Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$111,656
in 2 filings

Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-06-18 Humer Franz B Director Grant or award · Restricted Stock Unit +95,400 95,400
2025-06-18 Humer Franz B Director Grant or award · Restricted Stock Unit +95,400 95,400
2024-12-05 Humer Franz B Director Sale −9,221 $2.16 $20K 307,507
2024-06-05 Humer Franz B Director Grant or award +61,475 316,728
2024-06-05 Humer Franz B Director Grant or award · Stock Option (Right to buy) +95,541 95,541
2024-05-30 Humer Franz B Director Sale −11,200 $2.34 $26K 255,253
2023-06-13 Humer Franz B Director Grant or award +74,561 266,453
2022-06-15 Humer Franz B Director Grant or award +44,178 191,892
2021-06-10 Humer Franz B Director Grant or award +16,498 147,714
2020-06-05 Humer Franz B Director Grant or award +9,969 131,216
2019-06-06 Humer Franz B Director Grant or award +16,377 121,247
2018-10-15 Humer Franz B Director Purchase +30,000 $18.00 $540K 30,000
2018-10-15 Humer Franz B Director Conversion +74,870 104,870
2018-10-15 Humer Franz B Director Conversion · Series A Convertible Preferred Stock −14,261 0

Page 1 of 1 · 14 trades